Comparison Between Oral Methotrexate and Tofacitinib in Chronic Plaque Psoriasis
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Early Phase 1
SUMMARY
Psoriasis is a chronic inflammatory dermatoses which include well demarcated scaly erythematous plaques on whole body including scalp role of methotrexate vs tofacitinib is compared in this study
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 70
Healthy Volunteers: t
View:
• Patients aged 18- 70 years of either gender.
• Only patients with Psoriasis Area and Severity Index (PASI) score of 10 or above, and/or Body Surface Area (BSA) involvement of 10% or more, will be included.
• Duration of plaque psoriasis for at least 6 months prior to the study.
• Psoriasis that has not shown adequate response to topical therapies
Locations
Other Locations
Pakistan
Lahore general hospital
RECRUITING
Lahore
Contact Information
Primary
Maryam Fatima, Mbbs
maryamfatima726@yahoo.com
03361409014
Time Frame
Start Date: 2025-08-29
Estimated Completion Date: 2025-12-25
Participants
Target number of participants: 75
Treatments
Active_comparator: Group mTX
Methotrexate is a modified antirheumatic drug work by inhibiting dihydrofolate reductase
Active_comparator: Tofacitinib
Tofacitinib is janus kinase inhibitor and had a role in treatment of psoriasis and psoriatic arthritis
Related Therapeutic Areas
Sponsors
Leads: Lahore General Hospital